To further probe the role of induced ADRB2 activity in NSCLC cell line resistance to apatinib, we inhibited ADRB2 signaling activity with an ADRB2 antagonist, ICI118551. This evidence concerns the gene ADRB2 and non-small cell lung carcinoma.